You are here

A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.

Last updated on May 10, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Chandler, Arizona, 85286 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Dry Eye Syndromes
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Symptoms of dry eye for at least 6 months.

- Signs of moderate to severe dry eye

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Women who are nursing or pregnant

- Participation in other studies within 30 days of screening visit

- Ocular disorders that may confound interpretation of study results

NCT00784719
Pfizer
Completed
A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Age-Related Maculopathy, Age-Related Maculopathies, Eye Diseases, Retinal Degeneration, Macular Degeneration
NCT00877032
All Genders
18+
Years
Multiple Sites
Age-Related Maculopathy, Age-Related Maculopathies, Eye Diseases, Retinal Degeneration, Macular Degeneration
NCT01003691
All Genders
60+
Years
Multiple Sites
Dry Eye Syndromes
NCT01135511
All Genders
20+
Years
Multiple Sites
A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.
A Phase I/II Prospective, Randomized, Double Masked, Vehicle And Comparator Controlled, Dose Ranging Study Of CP-690,550 In Subjects With Dry Eye Disease.
A prospective, randomized, placebo and active comparator controlled study of CP-690,550 in subjects with dry eye.
Not Provided
Interventional
Phase 1
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Dry Eye Syndromes
  • Drug: CP-690,550
    Ophthalmic topical solution, low dose, dosed at least once/day, 8 weeks
  • Drug: CP-690,550
    Ophthalmic topical solution, medium dose, dosed at least once/day, 8 weeks
  • Drug: CP-690,550
    Ophthalmic topical solution, intermediate dose, dosed at least once/day, 8 weeks
  • Drug: CP-690,550
    Ophthalmic topical solution, high dose, dosed at least once/day, 8 weeks
  • Drug: Cyclosporine
    Ophthalmic topical solution, 0.05%, dosed at least once/day, 8 weeks
  • Drug: CP-690,550 Vehicle
    Ophthalmic topical solution, dosed at least once/day, 8 weeks
  • Experimental: Treatment 1
    Intervention: Drug: CP-690,550
  • Experimental: Treatment 2
    Intervention: Drug: CP-690,550
  • Experimental: Treatment 3
    Intervention: Drug: CP-690,550
  • Experimental: Treatment 4
    Intervention: Drug: CP-690,550
  • Active Comparator: Active comparator
    Intervention: Drug: Cyclosporine
  • Placebo Comparator: Placebo
    Intervention: Drug: CP-690,550 Vehicle


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
327
October 2009
October 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Symptoms of dry eye for at least 6 months.
  • Signs of moderate to severe dry eye

Exclusion Criteria:

  • Women who are nursing or pregnant
  • Participation in other studies within 30 days of screening visit
  • Ocular disorders that may confound interpretation of study results
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00784719
A3921034
A3921034
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
February 2013

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now